RU2744959C2 - Новые анти-pd-l1 антитела - Google Patents

Новые анти-pd-l1 антитела Download PDF

Info

Publication number
RU2744959C2
RU2744959C2 RU2018124602A RU2018124602A RU2744959C2 RU 2744959 C2 RU2744959 C2 RU 2744959C2 RU 2018124602 A RU2018124602 A RU 2018124602A RU 2018124602 A RU2018124602 A RU 2018124602A RU 2744959 C2 RU2744959 C2 RU 2744959C2
Authority
RU
Russia
Prior art keywords
antibody
seq
antibodies
binding
cells
Prior art date
Application number
RU2018124602A
Other languages
English (en)
Russian (ru)
Other versions
RU2018124602A (ru
RU2018124602A3 (https=
Inventor
Суемин ЦЯНЬ
Тэн ФЭЙ
Чжэнь ЛИ
Original Assignee
Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд filed Critical Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд
Publication of RU2018124602A publication Critical patent/RU2018124602A/ru
Publication of RU2018124602A3 publication Critical patent/RU2018124602A3/ru
Application granted granted Critical
Publication of RU2744959C2 publication Critical patent/RU2744959C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2018124602A 2016-03-23 2017-02-10 Новые анти-pd-l1 антитела RU2744959C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/077082 2016-03-23
CN2016077082 2016-03-23
PCT/CN2017/073242 WO2017161976A1 (en) 2016-03-23 2017-02-10 Novel anti-pd-l1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021106377A Division RU2776121C2 (ru) 2016-03-23 2017-02-10 Новые анти-pd-l1 антитела

Publications (3)

Publication Number Publication Date
RU2018124602A RU2018124602A (ru) 2020-01-14
RU2018124602A3 RU2018124602A3 (https=) 2020-03-06
RU2744959C2 true RU2744959C2 (ru) 2021-03-17

Family

ID=59900827

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018124602A RU2744959C2 (ru) 2016-03-23 2017-02-10 Новые анти-pd-l1 антитела

Country Status (8)

Country Link
US (2) US10822416B2 (https=)
EP (1) EP3433277A4 (https=)
JP (3) JP7080213B2 (https=)
KR (1) KR102937285B1 (https=)
CN (2) CN108779180B (https=)
CA (1) CA3007135A1 (https=)
RU (1) RU2744959C2 (https=)
WO (1) WO2017161976A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2792237C2 (ru) * 2018-09-06 2023-03-21 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Гуманизированные анти-c5 антитела и их применение

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106243225B (zh) * 2015-06-11 2021-01-19 智翔（上海）医药科技有限公司 新型抗-pd-l1抗体
CN108779180B (zh) * 2016-03-23 2020-10-16 迈博斯生物医药(苏州)有限公司 新型抗-pd-l1抗体
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
JP7021454B2 (ja) * 2017-02-03 2022-02-17 株式会社三洋物産 遊技機
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP7402158B2 (ja) * 2017-11-30 2023-12-20 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体及びｐｄ－ｌ１を検出するためにそれを使用する方法
CN115925943A (zh) * 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
KR102845020B1 (ko) * 2017-12-28 2025-08-12 난징 레전드 바이오테크 씨오., 엘티디. Pd-l1에 대한 항체 및 변이체
KR20210056288A (ko) 2018-06-01 2021-05-18 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 질환 또는 병태를 치료하기 위한 조성물 및 그의 용도
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CN112739717B (zh) 2018-06-29 2025-02-11 璟尚生物制药公司 三特异性拮抗剂
BR112021000383A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a pd-l1
WO2020151572A1 (en) * 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
AU2020212767B2 (en) 2019-01-25 2025-01-30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating tumor
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
AU2020281535A1 (en) 2019-05-24 2022-01-27 Merck Patent Gmbh Combination therapies using CDK inhibitors
KR20220016155A (ko) * 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
CN110194798A (zh) * 2019-05-31 2019-09-03 杭州科兴生物科技有限公司 抗pd-l1单克隆抗体、片段及其医药用途
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
US20220356255A1 (en) * 2019-07-15 2022-11-10 Capella Bioscience Ltd Anti-pd-l1 antibodies
CN115038718B (zh) * 2019-11-08 2024-07-02 山东先声生物制药有限公司 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
EP4130041A4 (en) * 2020-03-31 2024-05-22 Biotheus Inc. ANTI-PD-L1 AND PD-L2 ANTIBODIES AND DERIVATIVES AND USE THEREOF
CN121319180A (zh) * 2020-07-28 2026-01-13 乐普生物科技股份有限公司 靶向PD-L1和TGF-β的双功能分子
AU2021322183A1 (en) * 2020-08-04 2023-03-02 Exelixis, Inc. PD-L1 binding agents and uses thereof
CN111929447B (zh) * 2020-09-24 2021-02-26 菁良基因科技(深圳)有限公司 一种pd-l1免疫组织化学参考品及其制备方法和应用
CA3201518A1 (en) * 2020-11-18 2022-05-27 Suzhou Transcenta Therapeutics Co., Ltd. Bi-functional molecules
CN112285366B (zh) * 2020-12-25 2021-06-08 南京广祺医药科技有限公司 一种测定血清中双特异性抗体BsAb的ELISA方法及应用
IL310292A (en) 2021-07-22 2024-03-01 Univ Dundee Medicinal myotains
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
WO2023040999A1 (zh) * 2021-09-18 2023-03-23 江苏康宁杰瑞生物制药有限公司 包含pd-l1抗原结合片段的组合物及其用途
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
TW202333785A (zh) * 2021-11-16 2023-09-01 中國大陸商蘇州創勝醫藥集團有限公司 Ｃｌａｕｄｉｎ１８．２拮抗劑和ｐｄ－１／ｐｄ－ｌ１軸抑制劑的組合療法
US20250282874A1 (en) * 2022-05-17 2025-09-11 Suzhou Transcenta Therapeutics Co., Ltd. Bifunctional protein, and preparation thereof and use thereof
CN114939161B (zh) * 2022-06-24 2023-02-28 南方医科大学南方医院 Pd-1抗体在制备治疗肌腱损伤的药物中的应用
CN120603849A (zh) * 2023-01-18 2025-09-05 科望(苏州)生物医药科技有限公司 抗pdl1单域抗体、融合蛋白及其用途
AR132623A1 (es) * 2023-05-08 2025-07-16 Hoffmann La Roche PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
WO2025240670A2 (en) * 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2416645C2 (ru) * 2009-05-04 2011-04-20 Общество с ограниченной ответственностью "Промоген-МАТ" Одноцепочечное антитело, связывающее фактор некроза опухоли альфа, днк, плазмидная днк и способ получения одноцепочечного антитела
CN103987405A (zh) * 2011-11-28 2014-08-13 默克专利股份公司 抗pd-l1抗体及其用途
CN104736168A (zh) * 2012-05-31 2015-06-24 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
CN104994873A (zh) * 2012-10-04 2015-10-21 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US8217849B2 (en) 2008-04-07 2012-07-10 Intelleflex Corporation Small profile antenna and RFID device having same
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010089411A2 (en) * 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
KR102056932B1 (ko) * 2011-10-10 2019-12-17 시티 오브 호프 메디토프와 메디토프-결합 항체 및 이들의 용도
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014165082A2 (en) * 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
KR102389677B1 (ko) * 2013-03-15 2022-04-21 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
CN108779180B (zh) 2016-03-23 2020-10-16 迈博斯生物医药(苏州)有限公司 新型抗-pd-l1抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2416645C2 (ru) * 2009-05-04 2011-04-20 Общество с ограниченной ответственностью "Промоген-МАТ" Одноцепочечное антитело, связывающее фактор некроза опухоли альфа, днк, плазмидная днк и способ получения одноцепочечного антитела
CN103987405A (zh) * 2011-11-28 2014-08-13 默克专利股份公司 抗pd-l1抗体及其用途
CN104736168A (zh) * 2012-05-31 2015-06-24 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
CN104994873A (zh) * 2012-10-04 2015-10-21 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2792237C2 (ru) * 2018-09-06 2023-03-21 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Гуманизированные анти-c5 антитела и их применение

Also Published As

Publication number Publication date
CN111363041A (zh) 2020-07-03
US11753473B2 (en) 2023-09-12
JP7080213B2 (ja) 2022-06-03
US20190330348A1 (en) 2019-10-31
CN108779180B (zh) 2020-10-16
US10822416B2 (en) 2020-11-03
WO2017161976A1 (en) 2017-09-28
RU2021106377A3 (https=) 2021-12-28
US20210009693A1 (en) 2021-01-14
JP7624484B2 (ja) 2025-01-30
CN108779180A (zh) 2018-11-09
KR20180127971A (ko) 2018-11-30
CN111363041B (zh) 2022-02-22
JP2022068161A (ja) 2022-05-09
RU2018124602A (ru) 2020-01-14
RU2018124602A3 (https=) 2020-03-06
JP2019516394A (ja) 2019-06-20
RU2021106377A (ru) 2021-03-31
JP2023171733A (ja) 2023-12-05
EP3433277A1 (en) 2019-01-30
KR102937285B1 (ko) 2026-03-11
JP7345578B2 (ja) 2023-09-15
EP3433277A4 (en) 2020-06-17
CA3007135A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
RU2744959C2 (ru) Новые анти-pd-l1 антитела
US11643465B2 (en) Anti-PD-1 antibodies
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
US20190367612A1 (en) Anti-gprc5d antibody and molecule containing same
AU2020202667A1 (en) Cd20 binding molecules and uses thereof
US20190367618A1 (en) Anti-pd-l1 antibody and application thereof
JP2021501744A (ja) 多重特異性抗体
KR20180116215A (ko) 암의 치료에 이용하기 위한 세포상해 유도 치료제
CN110144012A (zh) 用于治疗表达紧密连接蛋白的癌症疾病的制剂
AU2017379382A1 (en) Anti-CD3 Antibody and Molecules Comprising the Antibody
KR20220031738A (ko) 암 치료를 위한 항-fam19a5 항체의 용도
TW201916890A (zh) 抗ｐｄ－１抗體和抗ｌａｇ－３抗體聯合在製備治療腫瘤的藥物中的用途
CN114008077B (zh) 抗体和使用方法
CN114106182A (zh) 抗tigit的抗体及其用途
RU2776121C2 (ru) Новые анти-pd-l1 антитела
CN113368232B (zh) 多特异性抗原结合蛋白及其应用
HK40032298A (en) Novel anti-pd-l1 antibodies
HK40032298B (en) Novel anti-pd-l1 antibodies
HK1260737B (en) Novel anti-pd-l1 antibodies
HK1260737A1 (en) Novel anti-pd-l1 antibodies